Hypertension, a common side effect of bevacizumab linked to VEGF inhibition, is associated with a greater efficacy of this monoclonal antibody [11,12], and VEGF polymorphisms, which are predictive of bevacizumab-induced hypertension, are also correlated with the drug’s efficacy [11]. Here, VEGFA is linked to Hypertension.